Expression of proinflammatory cytokines in stable angina

Cover Page

Cite item

Full Text

Abstract

Objective: to evaluate the severity of immuno-inflammatory responses under stable stenocardia in patients with ischemic heart disease (IHD). Patients and intervention: the study included 83 patients suffering from IHD. Among them 30 cases were diagnosed as functional class (FC)-II stenocardia, 27 cases as FC-III stenocardia and 26 cases as FC-IV stenocardia. The control group included 25 healthy persons. For characterizing the immuno-inflammatory responses we examined the level of C-reactive protein (CRP), pro-inflammatory (IL-1b, IL-6, TNF-α) and anti-inflammatory (IL-4, IL-10) cytokines by the immunoenzymic procedure. Results: FC-II stenocardia showed normal levels of CRP and pro-inflammatory cytokines. FC-III stenocardia was associated with a moderate increase in markers of an inflammation. FC-IV stenocardia was characterized by maximum levels of CRP and pro-inflammatory cytokines. Conclusion. The intensity of immuno-inflammatory responses depends on more or less serious course of stenocardia in patients with IHD.

About the authors

A. N Zakirova

Bashkortostan State Medical University

Email: a.n.zakirova@yandex.ru
д-р мед. наук, проф., зав. каф. клин. кардиологии ИПО ГБОУ ВПО БГМУ Минздрава РФ

N. E Zakirova

Bashkortostan State Medical University

д-р мед. наук, проф., зав. каф. клин. функциональной диагностики ИПО ГБОУ ВПО БГМУ Минздрава РФ

References

  1. Лутай М.И., Голикова И.П., Деяк С.И. Системное воспаление у пациентов с ишемической болезнью сердца. Укр. мед. журн. 2006; 2: 80–3.
  2. Ребров А.Л., Воскобой И.В. Роль воспалительных и инфекционных факторов в развитии атеросклероза. Терапевт. арх. 2004; 1: 78–82.
  3. Packard R, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54 (1): 24–38.
  4. Мерай И.А., Павликова Е.А. Роль воспаления в процессах атерогенеза и в развитии сердечно - сосудистых осложнений. Русский врач. 2008; 5: 3–6.
  5. Harrison D.G. Endothelial and oxidative stress. Clin Cardiol 1997; 20: 11–7.
  6. Насонов Е.В. Иммунологические аспекты атеросклероза. Терапевт. арх. 2002; 5: 80–5.
  7. Brunetti N, Troccoli R, Correale M et al. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol 2006; 109: 248–56.
  8. Hansson G.K. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352 (16): 1685–95.
  9. Pearson T. Markers of Inflammation and Cardiovascular Disease. Circulation 2003; 107: 499–511.
  10. Закирова Н.Э., Хафизов Н.Х., Закирова А.Н. Иммуновоспалительные реакции при ишемической болезни сердца. Рацион. фармакотерапия в кардиологии. 2007; 2: 16–9.
  11. Ridker P, Coak N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Score. Circulation 2004; 109: 1955–9.
  12. Павликова Е.А., Мерай И.А. Клиническое значение интерлейкина-6 и фактора некроза опухоли-α при ишемической болезни сердца. Кардиология. 2003; 8: 68–71.
  13. Палеев Ф.Н., Абудеева И.С., Москалец О.В., Белокопытова И.С. Изменения интерлейкина-6 при различных формах ишемической болезни сердца. Кардиология. 2010; 2: 69–72.
  14. Кухарчук В.В., Зыков К.А., Масенко В.П. Динамика воспалительного процесса у больных с острым коронарным синдромом и стабильной стенокардией. Кардиологический вестник. 2007; 2: 3–13.
  15. Volpato S, Guralnik J, Ferruci L. Cardiovascular disease, interleukin-6 and risk of mortality in older women. Circulotion 2001; 103: 947–53.
  16. Волков В.И., Серик С.А. Провоспалительные цитокины и растворимая молекула межклеточной адгезии при ишемической болезни сердца. Кардиология. 2002; 9: 12–6.
  17. Armstrong E, Morrow D, Salatine M. Inflammatory Biomarkers in Acute Coronary Sydromes. Part 1: Introduction and Cytokines. Circulation 2006; 113: 72–5.

Copyright (c) 2013 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies